Overview
HER3 antibody-drug conjugates represent an advanced class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. These biologics are engineered to selectively deliver chemotherapeutic agents to tumor cells expressing the HER3 receptor, a member of the EGFR family implicated in various cancers. The development of HER3 ADCs addresses the challenge of treating tumors with heterogeneous HER3 expression while minimizing systemic toxicity. Current clinical-stage candidates typically employ cleavable or non-cleavable linker technologies coupled with potent payloads such as auristatins or maytansinoids.
Physical and Chemical Properties
HER3 ADCs are complex macromolecules with properties dependent on their antibody scaffold, linker chemistry, and cytotoxic payload. The antibody component (typically IgG1) provides target specificity and accounts for the majority of the molecular weight, while the small-molecule drug contributes to therapeutic potency. Formulation stability is critical, with most commercial products supplied as lyophilized powders requiring reconstitution. The conjugated drugs typically exhibit reduced solubility compared to naked antibodies, necessitating specialized formulation buffers. pH stability generally ranges from 4.0-8.0, with optimal storage at refrigerated temperatures to prevent aggregation or hydrolysis of the linker.
Main Applications
HER3 ADCs are primarily investigated for oncology indications where HER3 overexpression or activation contributes to tumor progression and therapy resistance. Clinical trials focus on HER3-positive breast cancer (particularly HR+/HER2- subtypes), non-small cell lung cancer, and gastric cancers. Beyond monotherapy, combination approaches with EGFR inhibitors or chemotherapy are being explored to overcome compensatory signaling pathways. The precise targeting mechanism also shows promise for treating minimal residual disease and preventing metastasis in adjuvant settings.
Safety and Storage
As cytotoxic compounds, HER3 ADCs require careful handling per OSHA hazardous drug guidelines. Personnel should use appropriate PPE including nitrile gloves, protective eyewear, and closed-system transfer devices during preparation. Storage conditions must maintain chain of custody documentation and temperature monitoring (typically 2-8°C). Lyophilized products generally have longer shelf lives (12-24 months) than liquid formulations (3-6 months). Avoid repeated freeze-thaw cycles, and inspect for particulate matter or discoloration before use.
B2B Procurement Guide
When sourcing HER3 ADCs, verify the supplier's cGMP compliance and track record in ADC manufacturing. Key procurement considerations include batch-to-batch consistency, drug-antibody ratio (DAR) specifications, and residual solvent levels. For research quantities, request detailed characterization data including mass spectrometry analysis and in vitro potency assays. Clinical-grade materials require additional documentation including stability studies, immunogenicity assessments, and comprehensive safety testing. Lead times for custom conjugates typically range from 8-16 weeks depending on payload complexity.
Related Manufacturers
- 主营：抗体偶联药物、递送辅料、dlin-mc3-dma、peg衍生物
- 主营：碘海醇、葡甲胺、氨甲环酸、盐酸柔红霉素、甘油磷酸钠、海藻糖、葡乙胺、古龙酸、托吡酯、潮霉素B、替卡西林钠克拉维酸钾、星孢菌素、盐酸阿霉素、碘帕醇
- 主营：小分子现货、科研小分子、单抗、中间体、医药中间体、多肽、RAS抑制剂、实验室用试剂、实验小分子、氯苯甲酸、咪唑乙醇、氧代丙腈、贝达喹啉、贝伐单抗、谷氨酰胺、喹啉-21氢、决明内酯、溴喹唑啉、苯基丙基、乙基己基